1. Metabolic Enzyme/Protease
  2. Heme Oxygenase (HO)
  3. KCL-HO-1i

KCL-HO-1i 是一种口服活性的 heme oxygenase-1 (HO-1) 抑制剂 (大鼠 HO-1: IC50 = 123 nM,人 HO-1: IC50 = 128 nM)。KCL-HO-1i 针对肿瘤微环境 (TME) 中免疫抑制的 LYVE-1+ 血管周肿瘤相关巨噬细胞 (PvTAMs),减少 PvTAM 介导的免疫排斥。KCL-HO-1i 在 MMTV-PyMT 自发性乳腺癌小鼠或携带皮下 MN-MCA1 肉瘤的 C57Bl/6 小鼠中与化疗显示出协同抗肿瘤效果。KCL-HO-1i 可用于癌症研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

KCL-HO-1i

KCL-HO-1i Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

查看 Heme Oxygenase (HO) 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

KCL-HO-1i is an orally active heme oxygenase-1 (HO-1) inhibitor (rat HO-1: IC50 = 123 nM) and human HO-1: IC50 = 128 nM). KCL-HO-1i targets immunosuppressive LYVE-1+ perivascular tumor-associated macrophages (PvTAMs) in the tumor microenvironment (TME), reduces PvTAM-mediated immune exclusion. KCL-HO-1i demonstrates synergistic anti-tumor efficacy with chemotherapy in MMTV-PyMT spontaneous breast cancer mice or C57Bl/6 mice bearing subcutaneous MN-MCA1 sarcomas. KCL-HO-1i can be used for the study of cancer[1].

IC50 & Target[1]

HO-1

123 nM (IC50, rat splenic microsomes )

HO-1

128 nM (IC50, HEK293T cells )

体外研究
(In Vitro)

KCL-HO-1i 对大鼠脾微粒体中的大鼠 heme oxygenase-1 (HO-1) (IC50 = 123 nM) 和 HEK293T 细胞 (IC50 = 128 nM) 表现出抑制活性[1].
KCL-HO-1i (25 μM, 16 h) 改善 CD8+ T 细胞的跨内皮迁移,逆转了在 transwell 实验中由 IL-6 极化的骨髓源性巨噬细胞引起的迁移限制[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

KCL-HO-1i (27.8 mg/kg (25 μMol/kg),口服,每日一次,21 天) 单独使用可减缓肿瘤生长,并与化疗 (5-fluorouracil (HY-90006) 或 Gemcitabine (HY-17026)) 协同作用,在 MMTV-PyMT 自发性乳腺癌小鼠和携带皮下 MN-MCA1 肉瘤的 C57Bl/6 小鼠中实现持久的肿瘤生长控制[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Transgenic MMTV-PyMT mice (FVB/N background) with spontaneous breast tumor development or MN-MCA1 sarcoma cells (2.5 × 105 in 100 µL RPMI 1640) were subcutaneously implanted into the flanks of 21-25 g female C57Bl/6 mice to establish ectopic sarcoma tumorsMN-MCA1 sarcoma cells (2.5 × 10⁵ in 100 µL RPMI 1640) were subcutaneously implanted into the flanks of 21-25 g female C57Bl/6 mice to establish ectopic sarcoma tumors[1]
Dosage: p.o., daily, 21 days
Administration: 25 μMol/kg, alone or combined with chemotherapy (5-fluorouracil (40 mg/kg/4 days) or Gemcitabine (6.6 mg/kg/7 days)
Result: Achieved tumor growth control.
Caused mild pulmonary inflammation (grade 2-3) in mice.
Reduced the expression of TIM3 (an inhibitory immune checkpoint receptor) on CD8+ T-cells.
分子量

1110.75

Formula

C34H36N4O12P2Sn3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
KCL-HO-1i
目录号:
HY-175660
需求量: